title: Severe malnutrition and metabolic complications of HIV-infected children in the antiretroviral era: clinical care and management in resource-limited settings.
abstract: More than 2 million children globally are living with HIV infection and >90% of these reside in sub-Saharan Africa. Severe acute malnutrition (SAM) remains a major problem for HIV-infected children who live in resource-limited settings (RLS), and SAM is an important risk factor for mortality. SAM in HIV-infected children is associated with complications including electrolyte disorders, micronutrient deficiencies, and severe infections, which contribute to the high mortality. Access to antiretroviral therapy (ART) has significantly improved the survival of HIV-infected children, although the response to ART of children with SAM remains undocumented in the literature. Immune and virologic responses to ART in RLS are similar to those of infected children in resource-rich settings, but delays in initiation of therapy have led to a high early mortality. Antiretroviral drug toxicities have been described in children who receive therapy and may affect their quality of life and long-term survival. Metabolic complications of ART include lipodystrophy, dyslipidemia, lactic acidosis, insulin resistance, and osteopenia. These complications have been well described in adults and children from developed countries, but data from RLS are limited, and these complications may be compounded by SAM. In this article we review the epidemiology, clinical presentation, and complications of SAM in HIV-infected children and the metabolic complications of HIV-infected children in the era of ART, and discuss future research priorities for RLS.
authors.affiliation: Department of Paediatrics and Child Health, Makerere University, Kampala, Uganda. pmusoke@mujhu.org
authors.forename: Philippa M
authors.initials: PM
authors.lastname: Musoke
authors.forename: Pamela
authors.initials: P
authors.lastname: Fergusson
mesh_terms: D017954:Africa South of the Sahara / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019468:Disease Management; D015658:HIV Infections / Q000150:complications* / Q000401:mortality; D006295:Health Resources; D006801:Humans; D008659:Metabolic Diseases / Q000209:etiology*; D009752:Nutritional Status; D011203:Poverty; D011502:Protein-Energy Malnutrition / Q000150:complications* / Q000453:epidemiology
chemical_list: D019380:Anti-HIV Agents
references.citation: Lancet. 2006 Dec 2;368(9551):1992-2000
references.pmid: 17141707
references.citation: AIDS. 2009 Jul 31;23(12):1501-9
references.pmid: 19550288
references.citation: South Afr J HIV Med. 2009 Dec;10(4):76-80
references.pmid: 20706598
references.citation: BMC Pediatr. 2010 Aug 06;10:56
references.pmid: 20691045
references.citation: Pediatrics. 2004 Aug;114(2):e235-42
references.pmid: 15286262
references.citation: Am J Ther. 2006 May-Jun;13(3):248-60
references.pmid: 16772767
references.citation: Pediatrics. 2002 Feb;109(2):E25
references.pmid: 11826235
references.citation: Malawi Med J. 2009 Sep;21(3):108-12
references.pmid: 20345019
references.citation: Cochrane Database Syst Rev. 2010 Dec 08;(12):CD003650
references.pmid: 21154354
references.citation: BMJ. 2003 Nov 1;327(7422):1019
references.pmid: 14593035
references.citation: Expert Opin Drug Metab Toxicol. 2008 Jan;4(1):37-49
references.pmid: 18370857
references.citation: J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):339-46
references.pmid: 16131991
references.citation: J Diabetes Sci Technol. 2010 Mar 01;4(2):258-62
references.pmid: 20307386
references.citation: Nutr J. 2006 Oct 16;5:27
references.pmid: 17042940
references.citation: AIDS. 2001 Sep 28;15(14):1823-9
references.pmid: 11579244
references.citation: Pediatrics. 2011 Feb;127(2):e423-41
references.pmid: 21262891
references.citation: Expert Opin Drug Saf. 2004 May;3(3):199-208
references.pmid: 15155148
references.citation: HIV Med. 2011 Sep;12(8):453-62
references.pmid: 21265979
references.citation: Pediatrics. 2010 May;125(5):e1039-47
references.pmid: 20385636
references.citation: Bone. 2010 Jun;46(6):1633-8
references.pmid: 20211284
references.citation: Trans R Soc Trop Med Hyg. 2009 Jun;103(6):541-8
references.pmid: 19058824
references.citation: SADJ. 2002 Dec;57(11):454-6
references.pmid: 12674865
references.citation: J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):384-92
references.pmid: 18931630
references.citation: AIDS. 2008 Jan 2;22(1):97-105
references.pmid: 18090397
references.citation: Antivir Ther. 2007;12(8):1247-54
references.pmid: 18240864
references.citation: Paediatr Drugs. 2010 Jun;12(3):187-99
references.pmid: 20481647
references.citation: J Acquir Immune Defic Syndr. 2006 Aug 15;42(5):637-45
references.pmid: 16868501
references.citation: BMC Pediatr. 2006 Mar 16;6:7
references.pmid: 16542415
references.citation: Lancet Infect Dis. 2008 Aug;8(8):477-89
references.pmid: 18652994
references.citation: Indian J Pediatr. 2009 Oct;76(10):1017-21
references.pmid: 19907933
references.citation: Pediatr Infect Dis J. 2006 May;25(5):427-31
references.pmid: 16645507
references.citation: Nutr Metab (Lond). 2009 Dec 01;6:50
references.pmid: 19951418
references.citation: Pediatrics. 2009 Feb;123(2):e347-51
references.pmid: 19124582
references.citation: Am J Clin Nutr. 2003 Aug;78(2):302-7
references.pmid: 12885713
references.citation: Pediatr Infect Dis J. 2004 Jun;23(6):536-43
references.pmid: 15194835
references.citation: Clin Infect Dis. 2003 Apr 1;36(Suppl 2):S69-78
references.pmid: 12652374
references.citation: AIDS. 2011 Apr 24;25(7):951-6
references.pmid: 21487251